A Study of Tumor Markers to Assess Risk of Recurrence of Liver Cancer After a Liver Transplant


About this study

The purpose of this study is evaluation of tumoral markers at the time of transplant to assess recurrence risk, and assessment of tumor sensitivity to a panel of candidate therapeutics as a guide to adjunct or therapeutic therapies for recurrent hepatocellular cancers (HCC).  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients on the waiting list for liver transplantation with liver cancer, with any etiology
  • Effort will be made to enroll at least 2/3 of patients who have had chronic HCV infection and prior treatment with direct acting antivirals with HCV eradication. 

Exclusion Criteria:

  • Children aged <18 years of age 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Tushar Patel, M.B., Ch.B.

Closed for enrollment

Contact information:

Lori Chase B.S., CCRP


More information


Publications are currently not available

Mayo Clinic Footer